Interpace Receives NY State Department of Health Approval for MicroRNA Thyroid Test | GenomeWeb

NEW YORK (GenomeWeb) – Interpace Diagnostics announced yesterday that the New York State Department of Health (NYSDOH) has approved its ThyraMir thyroid cancer classifier test.

ThyraMir analyzes the expression of 10 cancer-linked microRNAs to classify thyroid nodules as cancerous or benign following indeterminate results from fine-needle aspirate and biopsy samples. It is typically used in conjunction with Interpace's ThyGenX oncogene panel.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.